ERYTECH to Participate in
the
If you are interested in arranging a one-on-one meeting, please contact your conference representative.
About ERYTECH and eryaspase
ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.
The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cells’ altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. An investigator sponsored Phase 2 trial (IST) in acute lymphoblastic leukemia recently reported positive results, and a Phase 1 IST in 1L advanced pancreatic cancer is ongoing.
Eryaspase received Fast Track designation from the
ERYTECH produces its product candidates for treatment of patients in
ERYTECH is listed on the Nasdaq Global Select Market in
For more information, please visit www.erytech.com
CONTACTS
ERYTECH CFO & COO | Investor relations | NewCap Investor relations Nicolas Merigeau Media relations |
+33 4 78 74 44 38 investors@erytech.com | +1 (212) 915 2577 cdavis@lifesciadvisors.com | +33 1 44 71 94 94 erytech@newcap.eu |
Attachment
- ERYTECH_PR_
BTIG Conference curtain raiser_EN_vf
Source:
2021 GlobeNewswire, Inc., source